|Systematic (IUPAC) name|
|AHFS/Drugs.com||Consumer Drug Information|
|ATC code||A12CC05 (WHO)|
|Molar mass||288.494 g/mol|
|(what is this?)|
This form of magnesium supplementation has increased bioavailability compared to oxide and citrate. There were some promising clinical trials conducted in the 1960s that found a combination of magnesium and potassium aspartates had a positive effect on fatigue and they reduced muscle hyper-excitability. In its evaluation in 2005, the AFC Panel concluded that in humans the bioavailability of magnesium from magnesium L-aspartate was similar to that from other organic magnesium salts and the more soluble inorganic magnesium salts. Overall, it was concluded that organic salts of magnesium have the greatest water solubility and demonstrate a greater oral absorption and bioavailability compared to less soluble magnesium preparations such as magnesium oxide, magnesium hydroxide, magnesium carbonate and magnesium sulphate.
|Birth to 6 months||30 mg*||30 mg*|
|7–12 months||75 mg*||75 mg*|
|1–3 years||80 mg||80 mg|
|4–8 years||130 mg||130 mg|
|9–13 years||240 mg||240 mg|
|14–18 years||410 mg||360 mg||400 mg||360 mg|
|19–30 years||400 mg||310 mg||350 mg||310 mg|
|31–50 years||420 mg||320 mg||360 mg||320 mg|
|51+ years||420 mg||320 mg|
- Adequate Intake (AI)
Magnesium-L-aspartate 1230 mg (magnesium 122 mg) up to 3 times/day Dosage adjustment in renal impairment: Patients with severe renal failure should not receive magnesium due to toxicity from accumulation.
Magnesium supplements and other magnesium containing products, such as antacids, can bind with prescription medicines, reducing their effectiveness.
Aspartate and glutamate are excitatory neurotransmitters. At high doses (consumed either independently or in excess of other protein–containing foods), can potentially stimulate neurons to the point of injury or death. The most compelling evidence that glutamate and aspartate function as neurotransmitters came from the observation that at low concentrations they excite virtually every neuron in the central nervous system. Excitotoxicity has been identified in animal studies and found that aspartic acid loads on the same brain receptors as glutamic acid, causing brain lesions and neuroendocrine disorders, and to act in an additive fashion with glutamic acid.
When considering aspartate sources individually, the levels of exposure estimated in this opinion amount up to 6 g/day for calcium aspartate (equivalent to 100 mg/kg bw/day for a 60 kg individual), 5.8 g/day for magnesium aspartate (equivalent to 97 mg/kg bw/day), 4 g/day for potassium aspartate (equivalent to 67 mg/kg bw/day), 0.05 g/day for zinc aspartate (0.8 mg/kg bw/day) and 0.008 g/day for copper aspartate (0.1 mg/kg bw/day). These values are all below those reported to induce amino acid imbalance in intervention trials (6.3 g aspartate/day) and they are, respectively, 7, 7.2, 10.5, 875 and 7000 times lower than the NOAEL for aspartate identified from a 90-day rat study. Based on these margins of safety, the Panel concludes that the use of zinc and copper aspartate, as sources of zinc and copper at the proposed use levels, are not of safety concern but that the use of calcium, magnesium and potassium aspartate could be of safety concern because the margins of safety are considered too low. The Panel notes that if all sources would be used simultaneously, combined exposure will be 16 g/day (equivalent to 267 mg/kg bw/day), which is above the reported amounts inducing amino acid imbalance in intervention trials (6.3 g/day). Furthermore, this value is only 3 times lower than the NOAEL from the rat study and due to the low margin of safety the Panel considers this of safety concern. The Panel estimates that the exposure to aspartate from these food supplements should be added to the aspartate exposure arising from the diet.
Based on US data, estimates of the mean exposure to aspartic acid arising from the diet are 4.1 g/day (children 1-3 year old) to 9.3 g/day (males 19-30 year old) and at the 95th percentile 6.6 g/day (children 4-8 year old) to 12.9 g/day (males 19-50 year old). Under these conditions, estimates of maximum daily exposure to aspartate ions from the diet (13 g/day) and from calcium or magnesium aspartate supplements would be approximately 19 g/day6, and from potassium aspartate would be 17 g/day. Aspartate exposure estimates from zinc or copper supplementation would not significantly change aspartate exposure from the diet.Taken individually these levels of exposure are lower than those reported to induce amino acid imbalance in intervention trials, when aspartate exposure from the diet is also taken into consideration (19.3 g/day). However, when considering the potential total intake of aspartic ions arising from the diet and from a potential multi-mineral combination of all food supplements the exposure could add up to 29 g/day. In line with the SCF concerns, the Panel considers that the use of L-amino acids in food supplements should not give rise to a nutritional imbalance of the amino acids. Thus the Panel concludes that under these conditions aspartate ion exposure from a multi-mineral combination of this type could be of safety concern.
- "Magnesium L-aspartate". PubChem. Retrieved 31 December 2015.
- "Understanding Different Types of Magnesium". Retrieved 31 December 2015.
- "Opinion of the Scientific Pane l on Food Additives, Flavourings, Processing Aids and Materials in Contact with Foods on a request from the Commission related to Magnesium Aspartate as a mineral substance used as a source of magnesium in dietary foods for special medical purposes.". The EFSA Journal. 167: 1–6. 2005.
- "Magnesium aspartate, potassium aspartate, magnesium potassium aspartate, calcium aspartate, zinc aspartate, and copper aspartate as sources for magnesium, potassium, ca lcium, zinc, and copper added for nutritional purposes to food supplements" (PDF). The EFSA Journal (2008) 883, 1-23. Retrieved 31 December 2015.
- "Magnesium Fact Sheet for Health Professionals". NIH. Retrieved 31 December 2015.
- "Magnesium L-aspartate Hydrochloride". Baltimore Washington Health Center. Univ. of Maryland. Retrieved 31 December 2015.
- "magnesium aspartate HCl". WebMD. Retrieved 31 December 2015.
- "Oral magnesium supplementation". Retrieved 31 December 2015.
- Dingledine, Raymond. "Glutamate and Aspartate Are the Major Excitatory Transmitters in the Brain". NCBI. Retrieved 31 December 2015.
- "Technical dossier on DL-magnesium-aspartate-tetrahydrate. February 2005g. Submitted by Gradiens Ltd. Budapest, Hungary.".
- "Technical dossier on magnesium L-aspa rtate. May 2005h. Submitted by Health Food Manufacturer's Association. Surrey, England.".
- "Technical dossier on magnesium L-aspartat e. June 2005i. Submitted by Kiwi Farm b.v. Katwijk, Nederland.".